胃肠道神经内分泌肿瘤的诊断和治疗进展

摘要/Abstract

摘要： 胃肠道神经内分泌肿瘤（GINET）是起源于消化道肽能神经元和神经内分泌细胞的一类肿瘤，能产生肽类激素，引起类癌综合征，但临床上出现典型症状者较少见。由于诊断技术及对该病认识的进步，发病率有所上升。目前治疗措施是以手术切除为主，联合化疗、靶向治疗的综合疗法。

关键词: 胃肠道, 神经内分泌瘤, 诊断评估, 治疗方法

Abstract: 【Abstract】Gastrointestinal neuroendocrine tumor (GI-NET) originates from peptide neurons and neuroendocrine cells in gastrointestinal tract, and secrets peptide hormones, leading to carcinoid syndrome which rarely happens in clinical practice. Because of the improvement of diagnostic method and understanding of this rare disease, the morbidity is rising in recent years. The main treatments of GINET are surgery and comprehensive therapy, consisting of chemotherapy and targeted therapy.

Key words: Gastrointestinal tract, Neuroendocrine tumors, Diagnostic evaluation, Therapeutics

盛能全；杨逸；王志刚. 胃肠道神经内分泌肿瘤的诊断和治疗进展[J]. 国际肿瘤学杂志, 2015, 42(4): 309-312.

Sheng-Neng-Quan-；Yang-Yi-；Wang-Zhi-Gang. 10.3760/cma.j.issn.1673-422X.2015.04.019[J]. Journal of International Oncology, 2015, 42(4): 309-312.

参考文献

［1］ Oberndorfer S. Karzinoide tumoren des dunndarms［J］. Frankf Z Pathol, 1907, 1: 426432. ［2］ Modlin IM, Lye KD, Kidd M. A 5decade annlysis of 13,715 carcinoid tumors［J］. Cancer, 2003, 97(4): 934959. ［3］ Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors［J］. Endocrinol Metab Clin North Am, 2011, 40(1): 118. ［4］ Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis［J］. J Gastroenterol, 2015, 50(1): 5864. ［5］ Tsai HJ, Wu CC, Tsai CR, et al. The epidemiology of neuroendocrine tumors in Taiwan: a nationwide cancer registrybased study［J］. PLoS One, 2013, 8(4): e62487. ［6］ Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems［J］. Pancreas, 2010, 39(6): 707712. ［7］ Pape UF, Berndt U, MüllerNordhorn J, et al. Prognostic factors of longterm outcome in gastroenteropancreatic neuroendocrine tumours［J］. Endocr Relat Cancer, 2008,15(4): 10831097. ［8］ Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors［J］. Endocrinol Metab Clin North Am, 2011, 40(1): 111314. ［9］ Dronamraju SS, Joypaul VB. Management of gastrointestinal carcinoid tumours  10 years experience at a district general hospital［J］. J Gastrointest Oncol, 2012, 3(2): 120129. ［10］ Gnanaseqaran G, O′Doherty MJ. Imaging neuroendocrine tumours with radionuclide techniques［J］. Minerva Endocrinol, 2008, 33(2):105126. ［11］中国胃肠胰神经内分泌肿瘤病理专家组.中国胃肠胰神经内分泌肿瘤病理学诊断共识［J］. 中华病理学杂志, 2011, 40(4): 257262. ［12］ Knigge U, Hansen CP. Surgery for GEPNETs［J］. Best Pract Res Clin Gastroenterol, 2012, 26(6): 819831. ［13］ Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study［J］. Endocr Relat Cancer, 2009, 16(3): 885894. ［14］ Scherübl H, Jensen RT, Cadiot G, et al. Management of early gastrointestinal neuroendocrine neoplasms［J］. World J Gastrointest Endosc, 2011, 3(7): 133139. ［15］ Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors［J］. N Engl J Med, 2011, 364(6): 501513. ［16］ Ahn HK, Choi JY, Kim KM, et al. Phase Ⅱ study of pazopanib monotherapy in mentastatic gastroenteropancreatic neuroendocrine tumours［J］. Br J Cancer, 2013, 109(6): 14141419. ［17］ Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors［J］. N Engl J Med, 2011, 364(6): 514523. ［18］ Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors［J］. World J Gastroenterol, 2010, 16(24): 29632970. ［19］ Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors［J］. N Engl J Med, 2014, 371(3): 224233. ［20］ Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: welldifferentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum［J］. Pancreas, 2010, 39(6): 753766. ［21］ Castao JP, Sundin A, Maecke HR, et al. Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges［J］. Cancer Metastasis Rev, 2014, 33(1): 353359. ［22］ Platanias LC. Mechanisms of typeⅠ and typeⅡinterferonmediated signaling［J］. Nat Rev Immunol, 2005, 5(5): 375386. ［23］ berg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Practice for diagnosis, treatment and followup［J］. Ann Oncol, 2012, 23 Suppl 7: vii124130. ［24］ Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin［J］. Endocr Relat Cancer, 2010, 17(1): R7590. ［25］ Casciano R, Wang X, Stern L, et al. International practice patterns and resource utilization in the treatment of neuroendocrine tumors［J］. Pancreas, 2013, 42(2): 339347. ［26］ Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)［J］. Gut, 2012, 61(1): 632.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[3]	过慈良, 江春平, 吴俊华. 肠道菌群与肿瘤免疫治疗[J]. 国际肿瘤学杂志, 2023, 50(7): 432-436.
[4]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[5]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[6]	罗澜, 陈创, 李昕倩, 孙圣荣. 细菌与乳腺癌的关系[J]. 国际肿瘤学杂志, 2021, 48(5): 292-295.
[7]	纪莉, 王璐, 钱东华. 胃肠道间质瘤肺转移一例[J]. 国际肿瘤学杂志, 2019, 46(2): 124-126.
[8]	万文泽，张睿智，李承果，杨文昶，王涛，曾祥宇，蔡明，王国斌，张鹏，陶凯雄. 胃肠间质瘤术后伊马替尼辅助治疗停止后复发、转移的诊治分析[J]. 国际肿瘤学杂志, 2018, 45(11): 665-669.
[9]	朱玉萍, 李德川, 刘卓. 青少年胃肠道间质瘤研究进展[J]. 国际肿瘤学杂志, 2014, 41(6): 447-450.
[10]	孙闻, 陈锦飞. 胃肠间质瘤生物标志物改变与患者预后及靶向药物疗效的关系[J]. 国际肿瘤学杂志, 2012, 39(4): 295-298.
[11]	张怡安, 朱畴文. 胃肠道间质瘤的预后评估[J]. 国际肿瘤学杂志, 2011, 38(5): 380-384.